Lyra Therapeutics (LYRA) EBT (2021 - 2025)
Historic EBT for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$6.0 million.
- Lyra Therapeutics' EBT rose 4959.55% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.9 million, marking a year-over-year increase of 6624.51%. This contributed to the annual value of -$93.4 million for FY2024, which is 4914.49% down from last year.
- According to the latest figures from Q3 2025, Lyra Therapeutics' EBT is -$6.0 million, which was up 4959.55% from -$7.4 million recorded in Q2 2025.
- Lyra Therapeutics' 5-year EBT high stood at -$6.0 million for Q3 2025, and its period low was -$48.1 million during Q2 2024.
- In the last 5 years, Lyra Therapeutics' EBT had a median value of -$13.6 million in 2021 and averaged -$14.6 million.
- Its EBT has fluctuated over the past 5 years, first tumbled by 20833.65% in 2024, then skyrocketed by 8454.87% in 2025.
- Lyra Therapeutics' EBT (Quarter) stood at -$13.6 million in 2021, then decreased by 4.44% to -$14.2 million in 2022, then decreased by 6.45% to -$15.1 million in 2023, then grew by 27.52% to -$11.0 million in 2024, then soared by 45.49% to -$6.0 million in 2025.
- Its last three reported values are -$6.0 million in Q3 2025, -$7.4 million for Q2 2025, and -$8.5 million during Q1 2025.